Want to see JP:5592 full AI Analyst Report?
5592 Stock Chart & Stats
¥2661.00
-¥9.00(-0.63%)
At close: 4:00 PM EST
¥2661.00
-¥9.00(-0.63%)
Day’s Range― - ―
52-Week Range¥2,065.00 - ¥4,685.00
Previous CloseN/A
Volume47.70K
Average Volume (3M)73.92K
Market Cap
¥27.98B
Enterprise Value¥26.83B
Total Cash (Recent Filing)¥5.20B
Total Debt (Recent Filing)¥2.82B
Price to Earnings (P/E)9.3
Beta0.81
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.56%
Share Statistics
EPS (TTM)263.13
Shares Outstanding11,459,482
10 Day Avg. Volume72,500
30 Day Avg. Volume73,916
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.41
Price to Sales (P/S)2.22
P/FCF Ratio9.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)188.9
Revenue Forecast (FY)¥14.30B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue & Earnings GrowthConsistent multi-year revenue and net income expansion demonstrates durable product-market fit and scalable unit economics. Growing top line and profits enhance ability to reinvest in the platform, fund strategic initiatives, and sustain long-term operating leverage across its healthcare/pharmacy services.
Strengthened Equity BaseA materially stronger equity position improves balance-sheet resilience and lowers solvency risk. Higher equity supports larger investments in digital platform development, M&A optionality, and buffer against cyclical shocks, making capital structure more durable for multi-year growth execution.
Cash-Flow RecoveryThe sharp cash-flow rebound restores internal funding capacity for operations and reinvestment, reducing reliance on external financing. Improved FCF in 2026 supports sustainable capex and working capital needs, strengthening long-term cash conversion and strategic optionality.
Bears Say
Large 2025 Cash OutflowA severe one-year cash outflow undermines cash predictability and signals potential working-capital, timing, or large investment swings. Such episodes raise liquidity and planning risk, complicating capital allocation and making multi-year cash forecasting and stability harder for stakeholders.
Volatile Leverage & Asset BaseWide swings in debt and asset levels point to structural balance-sheet changes or one-off transactions, increasing refinancing and valuation risk. This volatility reduces predictability of returns, complicates credit assessment, and can raise future funding costs during adverse cycles.
Limited Model Disclosure & GuidanceInsufficient public detail on revenue streams and no provided guidance limit investor visibility into recurring revenue quality and margin drivers. Lack of disclosure hampers long-term forecasting, obscures sustainability of growth, and raises governance and transparency concerns for durable analysis.
Kusurinomadoguchi, Inc. News
5592 FAQ
What was Kusurinomadoguchi, Inc.’s price range in the past 12 months?
Kusurinomadoguchi, Inc. lowest stock price was ¥2065.00 and its highest was ¥4685.00 in the past 12 months.
What is Kusurinomadoguchi, Inc.’s market cap?
Kusurinomadoguchi, Inc.’s market cap is ¥27.98B.
When is Kusurinomadoguchi, Inc.’s upcoming earnings report date?
Kusurinomadoguchi, Inc.’s upcoming earnings report date is Aug 14, 2026 which is in 24 days.
How were Kusurinomadoguchi, Inc.’s earnings last quarter?
Kusurinomadoguchi, Inc. released its earnings results on May 14, 2026. The company reported ¥73.87 earnings per share for the quarter, beating the consensus estimate of N/A by ¥73.87.
Is Kusurinomadoguchi, Inc. overvalued?
According to Wall Street analysts Kusurinomadoguchi, Inc.’s price is currently Overvalued.
Does Kusurinomadoguchi, Inc. pay dividends?
Kusurinomadoguchi, Inc. pays a Notavailable dividend of ¥40 which represents an annual dividend yield of 1.56%. See more information on Kusurinomadoguchi, Inc. dividends here
What is Kusurinomadoguchi, Inc.’s EPS estimate?
Kusurinomadoguchi, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kusurinomadoguchi, Inc. have?
Kusurinomadoguchi, Inc. has 11,459,482 shares outstanding.
What happened to Kusurinomadoguchi, Inc.’s price movement after its last earnings report?
Kusurinomadoguchi, Inc. reported an EPS of ¥73.87 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.51%.
Which hedge fund is a major shareholder of Kusurinomadoguchi, Inc.?
Currently, no hedge funds are holding shares in JP:5592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kusurinomadoguchi, Inc.
Kusurinomadoguchi, Inc., established in 2004 and headquartered in Tokyo, Japan, develops and implements a diverse array of technology solutions specifically designed for pharmacies and the wider medical care sector throughout the country. Its comprehensive platform includes patient-facing services such as the EPARK drug counter, an online portal for locating and booking appointments at pharmacies, and the EPARK medicine notebook, which enables digital management of family prescriptions and reservation for medication dispensations. The company also offers a dedicated site facilitating telephone medical consultations for over-the-counter medicines, alongside a system allowing patients to select their preferred pharmacy for services, and provides online medication guidance as well as hospital-supported online consultations. For pharmacy operations and management, Kusurinomadoguchi delivers Health Tech Navi, an electronic medication history system, and the Care Daisy system, which integrates various recording tools and ICT devices. It further provides procurement solutions for pharmaceuticals, including a marketplace for dispensing pharmacies to efficiently buy and sell surplus or slow-moving inventory, extending to the management and acquisition of otherwise stagnant stock. The firm also features a centralized management system to streamline outpatient reception, appointment scheduling, and online medical treatments. Additionally, it offers Pharmacy Support, a robust customer relationship management (CRM) system tailored for engaging repeat patients, alongside specialized operational systems for dispensing pharmacies and a matching service connecting nursing care facilities with appropriate pharmacies.